EXPLORing Arthritis with Total-body Positron Emission Tomography

Abstract

Arthritis has significant adverse consequences on musculoskeletal tissues and often other organs of the body. Current methods for clinical evaluation of arthritis are suboptimal, and biomarkers that are objective and measurable indicators for monitoring of arthritis disease activity are in critical demand. Recently, total-body positron emission tomography (PET) has been developed that can collect imaging signals synchronously from the entire body at ultra-low doses and reduced scan times. These scanners have increased signal collection efficiency that overcomes several limitations of standard PET scanners in the evaluation of arthritis, and they may potentially provide biomarkers to assess local and systemic impact of the arthritis disease process. This article reviews current results from using total-body PET in the assessment of common arthritic conditions, and it outlines future opportunities and challenges.

Keywords

total-body positron emission tomography - rheumatoid arthritis - psoriatic arthritis - osteoarthritis - molecular imaging

Publikationsverlauf

Artikel online veröffentlicht:
07. November 2023

• References

• 1 Barbour KE, Helmick CG, Boring M, Brady TJ. Vital signs: prevalence of doctor-diagnosed arthritis and arthritis-attributable activity limitation—United States, 2013-2015. MMWR Morb Mortal Wkly Rep 2017; 66 (09) 246-253
• 2 Brennan-Olsen SL, Cook S, Leech MT. et al. Prevalence of arthritis according to age, sex and socioeconomic status in six low and middle income countries: analysis of data from the World Health Organization study on global AGEing and adult health (SAGE) Wave 1. BMC Musculoskelet Disord 2017; 18 (01) 271
• 3 United States Bone and Joint Initiative. The Burden of Musculoskeletal Diseases in the United States (BMUS). 4th ed. 2020. Available at: http://www.boneandjointburden.orgexternal Accessed July 29, 2023
• 4 Luque Ramos A, Redeker I, Hoffmann F, Callhoff J, Zink A, Albrecht K. Comorbidities in patients with rheumatoid arthritis and their association with patient-reported outcomes: results of claims data linked to questionnaire survey. J Rheumatol 2019; 46 (06) 564-571
• 5 Husni ME, Merola JF, Davin S. The psychosocial burden of psoriatic arthritis. Semin Arthritis Rheum 2017; 47 (03) 351-360
• 6 Favalli EG, Biggioggero M, Crotti C, Becciolini A, Raimondo MG, Meroni PL. Sex and management of rheumatoid arthritis. Clin Rev Allergy Immunol 2019; 56 (03) 333-345
• 7 Srikanth VK, Fryer JL, Zhai G, Winzenberg TM, Hosmer D, Jones G. A meta-analysis of sex differences prevalence, incidence and severity of osteoarthritis. Osteoarthritis Cartilage 2005; 13 (09) 769-781
• 8 Iragorri N, Hazlewood G, Manns B, Danthurebandara V, Spackman E. Psoriatic arthritis screening: a systematic review and meta-analysis. Rheumatology (Oxford) 2019; 58 (04) 692-707
• 9 Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet 2016; 388 (10055): 2023-2038
• 10 Rida MA, Chandran V. Challenges in the clinical diagnosis of psoriatic arthritis. Clin Immunol 2020; 214: 108390
• 11 Zhang R, Yang X, Wang J. et al. Identification of potential biomarkers for differential diagnosis between rheumatoid arthritis and osteoarthritis via integrative genome-wide gene expression profiling analysis. Mol Med Rep 2019; 19 (01) 30-40
• 12 Harnden K, Pease C, Jackson A. Rheumatoid arthritis. BMJ 2016; 352: i387
• 13 Verweij CL. Predicting the future of anti-tumor necrosis factor therapy. Arthritis Res Ther 2009; 11 (03) 115
• 14 Evangelisto A, Wakefield R, Emery P. Imaging in early arthritis. Best Pract Res Clin Rheumatol 2004; 18 (06) 927-943
• 15 Roemer FW, Guermazi A, Trattnig S. et al. Whole joint MRI assessment of surgical cartilage repair of the knee: Cartilage Repair OsteoArthritis Knee Score (CROAKS). Osteoarthritis Cartilage 2014; 22 (06) 779-799
• 16 Takase K, Ohno S, Takeno M. et al. Simultaneous evaluation of long-lasting knee synovitis in patients undergoing arthroplasty by power Doppler ultrasonography and contrast-enhanced MRI in comparison with histopathology. Clin Exp Rheumatol 2012; 30 (01) 85-92
• 17 Michelsen B, Diamantopoulos AP, Soldal DM, Hammer HB, Kavanaugh A, Haugeberg G. Achilles enthesitis defined by ultrasound is not associated with clinical enthesitis in patients with psoriatic arthritis. RMD Open 2017; 3 (02) e000486
• 18 Singla S, Eder L, Kaeley G, Aydin SZ. The use and availability of musculoskeletal ultrasonography for psoriatic disease among group for research and assessment of psoriasis and psoriatic arthritis members and the unmet needs. Clin Ther 2023; S0149-2918 (23)00199-6
• 19 Coates LC, Hodgson R, Conaghan PG, Freeston JE. MRI and ultrasonography for diagnosis and monitoring of psoriatic arthritis. Best Pract Res Clin Rheumatol 2012; 26 (06) 805-822
• 20 Poggenborg RP, Pedersen SJ, Eshed I. et al. Head-to-toe whole-body MRI in psoriatic arthritis, axial spondyloarthritis and healthy subjects: first steps towards global inflammation and damage scores of peripheral and axial joints. Rheumatology (Oxford) 2015; 54 (06) 1039-1049
• 21 Krabbe S, Eshed I, Gandjbakhch F. et al; OMERACT MRI in Arthritis Working Group. Development and Validation of an OMERACT MRI Whole-Body Score for Inflammation in Peripheral Joints and Entheses in Inflammatory Arthritis (MRI-WIPE). J Rheumatol 2019; 46 (09) 1215-1221
• 22 Husic R, Gretler J, Felber A. et al. Disparity between ultrasound and clinical findings in psoriatic arthritis. Ann Rheum Dis 2014; 73 (08) 1529-1536
• 23 Fassio A, Matzneller P, Idolazzi L. Recent advances in imaging for diagnosis, monitoring, and prognosis of psoriatic arthritis. Front Med (Lausanne) 2020; 7: 551684
• 24 Roivainen A, Parkkola R, Yli-Kerttula T. et al. Use of positron emission tomography with methyl-11C-choline and 2-18F-fluoro-2-deoxy-D-glucose in comparison with magnetic resonance imaging for the assessment of inflammatory proliferation of synovium. Arthritis Rheum 2003; 48 (11) 3077-3084
• 25 van der Laken CJ, Elzinga EH, Kropholler MA. et al. Noninvasive imaging of macrophages in rheumatoid synovitis using 11C-(R)-PK11195 and positron emission tomography. Arthritis Rheum 2008; 58 (11) 3350-3355
• 26 Verweij NJF, Yaqub M, Bruijnen STG. et al. First in man study of [¹⁸F]fluoro-PEG-folate PET: a novel macrophage imaging technique to visualize rheumatoid arthritis. Sci Rep 2020; 10 (01) 1047
• 27 Shrestha S, Kim MJ, Eldridge M. et al. PET measurement of cyclooxygenase-2 using a novel radioligand: upregulation in primate neuroinflammation and first-in-human study. J Neuroinflammation 2020; 17 (01) 140
• 28 Dietz M, Nicod Lalonde M, Omoumi P, Testart Dardel N, Hügle T, Prior JO. Imaging of ανβ3 integrin expression in rheumatoid arthritis with [68Ga]Ga-NODAGA-RGDyk PET/CT in comparison to [18F]FDG PET/CT. Med Nucl (Paris) 2021; 45 (5–6): 293-295
• 29 Zhu Z, Yin Y, Zheng K. et al. Evaluation of synovial angiogenesis in patients with rheumatoid arthritis using ⁶⁸Ga-PRGD2 PET/CT: a prospective proof-of-concept cohort study. Ann Rheum Dis 2014; 73 (06) 1269-1272
• 30 Viitanen R, Moisio O, Lankinen P. et al. First-in-humans study of ⁶⁸Ga-DOTA-Siglec-9, a PET ligand targeting vascular adhesion protein 1. J Nucl Med 2021; 62 (04) 577-583
• 31 Watanabe T, Takase-Minegishi K, Ihata A. et al. (18)F-FDG and (18)F-NaF PET/CT demonstrate coupling of inflammation and accelerated bone turnover in rheumatoid arthritis. Mod Rheumatol 2016; 26 (02) 180-187
• 32 Park HJ, Chang SH, Lee JW, Lee SM. Clinical utility of F-18 sodium fluoride PET/CT for estimating disease activity in patients with rheumatoid arthritis. Quant Imaging Med Surg 2021; 11 (04) 1156-1169
• 33 Narayan N, Owen DR, Taylor PC. Advances in positron emission tomography for the imaging of rheumatoid arthritis. Rheumatology (Oxford) 2017; 56 (11) 1837-1846
• 34 Mountz JM, Alavi A, Mountz JD. Emerging optical and nuclear medicine imaging methods in rheumatoid arthritis. Nat Rev Rheumatol 2012; 8 (12) 719-728
• 35 Cherry SR, Badawi RD, Karp JS, Moses WW, Price P, Jones T. Total-body imaging: transforming the role of positron emission tomography. Sci Transl Med 2017; 9 (381) eaaf6169
• 36 Badawi RD, Shi H, Hu P. et al. First human imaging studies with the EXPLORER total-body pet scanner. J Nucl Med 2019; 60 (03) 299-303
• 37 Spencer BA, Berg E, Schmall JP. et al. Performance evaluation of the uEXPLORER total-body PET/CT scanner Based on NEMA NU 2-2018 with additional tests to characterize PET scanners with a long axial field of view. J Nucl Med 2021; 62 (06) 861-870
• 38 Karp J, Schmall J, Geagan M. et al. Imaging performance of the PennPET Explorer scanner. J Nucl Med 2018; 59 (Suppl. 01) 222-222
• 39 Prenosil GA, Sari H, Fürstner M. et al. Performance characteristics of the Biograph Vision Quadra PET/CT System with a long axial field of view using the NEMA NU 2-2018 standard. J Nucl Med 2022; 63 (03) 476-484
• 40 Zhao YM, Li YH, Chen T. et al. Image quality and lesion detectability in low-dose pediatric ¹⁸F-FDG scans using total-body PET/CT. Eur J Nucl Med Mol Imaging 2021; 48 (11) 3378-3385
• 41 Zhang YQ, Hu PC, Wu RZ. et al. The image quality, lesion detectability, and acquisition time of ¹⁸F-FDG total-body PET/CT in oncological patients. Eur J Nucl Med Mol Imaging 2020; 47 (11) 2507-2515
• 42 Hu P, Zhang Y, Yu H. et al. Total-body ¹⁸F-FDG PET/CT scan in oncology patients: how fast could it be?. Eur J Nucl Med Mol Imaging 2021; 48 (08) 2384-2394
• 43 Pantel AR, Viswanath V, Daube-Witherspoon ME. et al. PennPET Explorer: human imaging on a whole-body imager. J Nucl Med 2020; 61 (01) 144-151
• 44 Alberts I, Hünermund JN, Prenosil G. et al. Clinical performance of long axial field of view PET/CT: a head-to-head intra-individual comparison of the Biograph Vision Quadra with the Biograph Vision PET/CT. Eur J Nucl Med Mol Imaging 2021; 48 (08) 2395-2404
• 45 van Sluis J, van Snick JH, Brouwers AH. et al. Shortened duration whole body 18F-FDG PET Patlak imaging on the Biograph Vision Quadra PET/CT using a population-averaged input function. EJNMMI Phys 2022; 9 (01) 1-14
• 46 Mannheim JG, Rausch I, Conti M, la Fougère C, Schmidt FP. Characterization of the partial volume effect along the axial field-of-view of the Biograph Vision Quadra total-body PET/CT system for multiple isotopes. EJNMMI Phys 2023; 10 (01) 33
• 47 McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011; 365 (23) 2205-2219
• 48 Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis: a review. JAMA 2018; 320 (13) 1360-1372
• 49 Gu JT, Nguyen L, Chaudhari AJ, MacKenzie JD. Molecular characterization of rheumatoid arthritis with magnetic resonance imaging. Top Magn Reson Imaging 2011; 22 (02) 61-69
• 50 Polisson RP, Schoenberg OI, Fischman A. et al. Use of magnetic resonance imaging and positron emission tomography in the assessment of synovial volume and glucose metabolism in patients with rheumatoid arthritis. Arthritis Rheum 1995; 38 (06) 819-825
• 51 Beckers C, Ribbens C, André B. et al. Assessment of disease activity in rheumatoid arthritis with (18)F-FDG PET. J Nucl Med 2004; 45 (06) 956-964
• 52 Chaudhari AJ, Ferrero A, Godinez F. et al. High-resolution (18)F-FDG PET/CT for assessing disease activity in rheumatoid and psoriatic arthritis: findings of a prospective pilot study. Br J Radiol 2016; 89 (1063): 20160138
• 53 Chaudhari AJ, Bowen SL, Burkett GW. et al. High-resolution (18)F-FDG PET with MRI for monitoring response to treatment in rheumatoid arthritis. Eur J Nucl Med Mol Imaging 2010; 37 (05) 1047
• 54 Kubota K, Ito K, Morooka M. et al. FDG PET for rheumatoid arthritis: basic considerations and whole-body PET/CT. Ann N Y Acad Sci 2011; 1228: 29-38
• 55 Yamashita H, Kubota K, Mimori A. Clinical value of whole-body PET/CT in patients with active rheumatic diseases. Arthritis Res Ther 2014; 16 (05) 423
• 56 Kubota K, Yamashita H, Mimori A. Clinical value of FDG-PET/CT for the evaluation of rheumatic diseases: rheumatoid arthritis, polymyalgia rheumatica, and relapsing polychondritis. Semin Nucl Med 2017; 47 (04) 408-424
• 57 Fosse P, Kaiser MJ, Namur G, de Seny D, Malaise MG, Hustinx R. ¹⁸F- FDG PET/CT joint assessment of early therapeutic response in rheumatoid arthritis patients treated with rituximab. Eur J Hybrid Imaging 2018; 2 (01) 6
• 58 Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38 (01) 44-48
• 59 Hammer HB, Michelsen B, Provan SA. et al. Tender joint count and inflammatory activity in patients with established rheumatoid arthritis: results from a longitudinal study. Arthritis Care Res (Hoboken) 2020; 72 (01) 27-35
• 60 Hammer HB, Michelsen B, Sexton J. et al. Swollen, but not tender joints, are independently associated with ultrasound synovitis: results from a longitudinal observational study of patients with established rheumatoid arthritis. Ann Rheum Dis 2019; 78 (09) 1179-1185
• 61 Hammer HB, Jensen Hansen IM, Järvinen P. et al. Rheumatoid arthritis patients with predominantly tender joints rarely achieve clinical remission despite being in ultrasound remission. Rheumatol Adv Pract 2021; 5 (02) rkab030
• 62 Abdelhafez Y, Raychaudhuri SP, Mazza D. et al. Total-body ¹⁸F-FDG PET/CT in autoimmune inflammatory arthritis at ultra-low dose: initial observations. J Nucl Med 2022; 63 (10) 1579-1585
• 63 Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med 2017; 376 (10) 957-970
• 64 Gladman DD. Clinical features and diagnostic considerations in psoriatic arthritis. Rheum Dis Clin North Am 2015; 41 (04) 569-579
• 65 Raychaudhuri SP, Wilken R, Sukhov AC, Raychaudhuri SK, Maverakis E. Management of psoriatic arthritis: early diagnosis, monitoring of disease severity and cutting edge therapies. J Autoimmun 2017; 76: 21-37
• 66 Wakefield RJ, Green MJ, Marzo-Ortega H. et al. Should oligoarthritis be reclassified? Ultrasound reveals a high prevalence of subclinical disease. Ann Rheum Dis 2004; 63 (04) 382-385
• 67 Mease PJ, Gladman DD, Papp KA. et al. Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. J Am Acad Dermatol 2013; 69 (05) 729-735
• 68 Chandran V, Abji F, Perruccio AV. et al. Serum-based soluble markers differentiate psoriatic arthritis from osteoarthritis. Ann Rheum Dis 2019; 78 (06) 796-801
• 69 Van Hal TW, Mulder MLM, Wenink MH. et al. Discovery of Psoriatic Arthritis in Psoriasis Patients for Early Rheumatological Referral (DAPPER) Study: a prospective observational cohort. Acta Derm Venereol 2022; 102: adv00768
• 70 McGonagle D, Hermann KG, Tan AL. Differentiation between osteoarthritis and psoriatic arthritis: implications for pathogenesis and treatment in the biologic therapy era. Rheumatology (Oxford) 2015; 54 (01) 29-38
• 71 Wahl RL, Dilsizian V, Palestro CJ. At last, ¹⁸F-FDG for inflammation and infection!. J Nucl Med 2021; 62 (08) 1048-1049
• 72 Basu S, Zhuang H, Torigian DA, Rosenbaum J, Chen W, Alavi A. Functional imaging of inflammatory diseases using nuclear medicine techniques. Semin Nucl Med 2009; 39 (02) 124-145
• 73 Felbo SK, Wiell C, Østergaard M. et al. Do tender joints in active psoriatic arthritis reflect inflammation assessed by ultrasound and magnetic resonance imaging?. Rheumatology (Oxford) 2022; 61 (02) 723-733
• 74 Hunter DJ, Collins JE, Deveza L, Hoffmann SC, Kraus VB. Biomarkers in osteoarthritis: current status and outlook - the FNIH Biomarkers Consortium PROGRESS OA study. Skeletal Radiol 2023 January 24 (Epub ahead of print)
• 75 Collins JE, Losina E, Nevitt MC. et al. Semiquantitative imaging biomarkers of knee osteoarthritis progression: data from the Foundation for the National Institutes of Health Osteoarthritis Biomarkers Consortium. Arthritis Rheumatol 2016; 68 (10) 2422-2431
• 76 Jarraya M, Roemer FW, Bäuerle T, Kogan F, Guermazi A. PET imaging in osteoarthritis. PET Clin 2023; 18 (01) 21-29
• 77 Jena A, Taneja S, Rana P. et al. Emerging role of integrated PET-MRI in osteoarthritis. Skeletal Radiol 2021; 50 (12) 2349-2363
• 78 Abdelhafez YG, Nardo L, Cherry SR, Badawi RD, Chaudhari AJ. 18F-Fluciclovine PET uptake in thumb carpometacarpal joint: initial observations. Paper presented at: Orthopaedics Research Society Annual Meeting; February 2–5, 2019; Austin, TX
• 79 Wu C, Li F, Niu G, Chen X. PET imaging of inflammation biomarkers. Theranostics 2013; 3 (07) 448-466
• 80 Yoon D, Kogan F, Gold GE, Biswal S. Identifying musculoskeletal pain generators using clinical PET. Semin Musculoskelet Radiol 2020; 24 (04) 441-450
• 81 Qi J, Matej S, Wang G, Zhang X. 3D/4D Reconstruction and quantitative total body imaging. PET Clin 2021; 16 (01) 41-54
• 82 Jiang J, Hua J, Wang H. et al. A virtual-pinhole PET device for improving contrast recovery and enhancing lesion detectability of a one-meter-long PET scanner: a simulation study. Phys Med Biol 2023;68)(14):
• 83 Shiyam Sundar LK, Lassen ML, Gutschmayer S. et al. Fully automated, fast motion correction of dynamic whole-body and total-body PET/CT imaging studies. J Nucl Med 2023; 64 (07) 1145-1153
• 84 Li EJ, Spencer BA, Schmall JP. et al. Efficient delay correction for total-body PET kinetic modeling using pulse timing methods. J Nucl Med 2022; 63 (08) 1266-1273
• 85 Richards JS, Dowell SM, Quinones ME, Kerr GS. How to use biologic agents in patients with rheumatoid arthritis who have comorbid disease. BMJ 2015; 351: h3658
• 86 Humphreys J, Hyrich K, Symmons D. What is the impact of biologic therapies on common co-morbidities in patients with rheumatoid arthritis?. Arthritis Res Ther 2016; 18 (01) 282